Developer of biotech platform disrupter designed for developing mRNA-based therapeutic drug products.
Developer of biotech platform disrupter designed for developing mRNA-based therapeutic drug products.
Other Pharmaceuticals and Biotechnology📍 Emeryville, CAFounded 2017
Current Valuation
$967M
as of 2022-Q1
PRIVATE
QL Price
$967M
0% vs last round
QuantLogix's current estimate for Nutcracker Therapeutics, published 2026-09-27 — in line with the last disclosed round of $967M (2022-Q1).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$967M
2022-Q1
weight 0.04
How this price has held up
No round has priced for Nutcracker Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Nutcracker Therapeutics, 2026-09-27 (cb6887cb41f3063d).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Nutcracker Therapeutics going public?
No. Nutcracker Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Nutcracker Therapeutics' valuation in 2026?
Nutcracker Therapeutics is valued at $967M as of 2022-Q1, set by its Series C ($167M, Mar 2022). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Nutcracker Therapeutics filed an S-1?
No public S-1 is on file for Nutcracker Therapeutics.
How much has Nutcracker Therapeutics raised?
Nutcracker Therapeutics has raised $241M in total, most recently a Series C of $167M in Mar 2022.
Is Nutcracker Therapeutics publicly traded — can you buy Nutcracker Therapeutics stock?
No. Nutcracker Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Nutcracker Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2017
HQ
Emeryville, CA
Employees
102
Total Raised
$241M
Last Round
Series C — $167M (Mar 2022)
IPO Status
private
Fundraising Status
Series C · $167M · 4y 6mo ago
privateTotal raised $241M
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series C
$167M
Mar 2022
—
$967M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Nutcracker Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-27. Re-checked weekly.
Talent Signal
No public careers page or job board could be found for Nutcracker Therapeutics as of 2026-09-16. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Health CarePharmaceuticalBiotechnologyTherapeutics
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2022-Q1. Refreshed quarterly.